CY1119476T1 - Αναστολεις της απομεθυλασης ιστονης - Google Patents
Αναστολεις της απομεθυλασης ιστονηςInfo
- Publication number
- CY1119476T1 CY1119476T1 CY20171101101T CY171101101T CY1119476T1 CY 1119476 T1 CY1119476 T1 CY 1119476T1 CY 20171101101 T CY20171101101 T CY 20171101101T CY 171101101 T CY171101101 T CY 171101101T CY 1119476 T1 CY1119476 T1 CY 1119476T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- cancer
- compositions
- suspensions
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται γενικά σε συνθέσεις και μεθόδους για την αντιμετώπιση του καρκίνου και της νεοπλασματικής νόσου. Παρέχονται εδώ υποκατεστημένες ενώσεις πυριδο[3,4-α]πυριμιδιν-4-όνης και φαρμακευτικές συνθέσεις που περιλαμβάνουν τις εν λόγω ενώσεις. Οι υπό διερεύνηση ενώσεις και συνθέσεις είναι χρήσιμες για την αναστολή της απομεθυλάσης ιστόνης. Περαιτέρω, οι ενώσεις και οι συνθέσεις της εφεύρεσης είναι χρήσιμες για την αγωγή του καρκίνου, όπως ο καρκίνος του προστάτη, ο καρκίνος του μαστού, ο καρκίνος της ουροδόχου κύστης, ο καρκίνος του πνεύμονα και/ή το μελάνωμα και άλλα παρόμοια.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361791406P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/024998 WO2014151106A1 (en) | 2013-03-15 | 2014-03-12 | Histone demethylase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119476T1 true CY1119476T1 (el) | 2018-03-07 |
Family
ID=51580888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171101101T CY1119476T1 (el) | 2013-03-15 | 2017-10-23 | Αναστολεις της απομεθυλασης ιστονης |
Country Status (16)
Country | Link |
---|---|
US (2) | US9994562B2 (el) |
EP (1) | EP2970211B1 (el) |
JP (1) | JP6332654B2 (el) |
AU (1) | AU2014235280B2 (el) |
CA (1) | CA2903465A1 (el) |
CY (1) | CY1119476T1 (el) |
DK (1) | DK2970211T3 (el) |
ES (1) | ES2644828T3 (el) |
HR (1) | HRP20171609T1 (el) |
HU (1) | HUE034906T2 (el) |
LT (1) | LT2970211T (el) |
PL (1) | PL2970211T3 (el) |
PT (1) | PT2970211T (el) |
RS (1) | RS56561B1 (el) |
SI (1) | SI2970211T1 (el) |
WO (1) | WO2014151106A1 (el) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150203453A1 (en) | 2012-10-02 | 2015-07-23 | Epitherapeutics Aps | Inhibitors of histone demethylases |
CN105263906B (zh) | 2013-02-27 | 2018-11-23 | 吉利德科学公司 | 组蛋白脱甲基酶的抑制剂 |
LT2970211T (lt) | 2013-03-15 | 2017-10-25 | Quanticel Pharmaceuticals Inc | Histono demetilazės inhibitoriai |
BR112017003442A2 (pt) | 2014-08-27 | 2017-11-28 | Gilead Sciences Inc | compostos e métodos para inibir histona desmetilases |
US10030017B2 (en) | 2014-09-17 | 2018-07-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
AU2015317806A1 (en) | 2014-09-17 | 2017-04-13 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
RU2684396C2 (ru) | 2014-10-29 | 2019-04-09 | Донг-А Ст Ко., Лтд. | Новые соединения пиридопиримидинона для модулирования каталитической активности гистонлизиндеметилаз (KDMS) |
CN107406414B (zh) * | 2015-01-09 | 2022-04-19 | 基因泰克公司 | 作为用于治疗癌症的组蛋白脱甲基酶kdm2b的抑制剂的(哌啶-3-基)(萘-2-基)甲酮衍生物 |
US20170057955A1 (en) * | 2015-08-26 | 2017-03-02 | Dong-A Socio Holdings Co., Ltd. | Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) |
WO2017161012A1 (en) * | 2016-03-15 | 2017-09-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
JP6770098B2 (ja) | 2016-05-27 | 2020-10-14 | ギリアード サイエンシーズ, インコーポレイテッド | Ns5a、ns5bまたはns3阻害剤を使用する、b型肝炎ウイルス感染症を処置するための方法 |
BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
SI3507276T1 (sl) | 2016-09-02 | 2022-01-31 | Gilead Sciences, Inc. | Spojine modulatorja toličnih receptorjev |
EP3526323B1 (en) | 2016-10-14 | 2023-03-29 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
AR110768A1 (es) | 2017-01-31 | 2019-05-02 | Gilead Sciences Inc | Formas cristalinas de tenofovir alafenamida |
JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
WO2018175670A1 (en) * | 2017-03-22 | 2018-09-27 | The Research Foundation For The State University Of New York | Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
CA3084582A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
MX2020008404A (es) | 2018-02-13 | 2020-09-25 | Gilead Sciences Inc | Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1). |
CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
KR20200140867A (ko) | 2018-04-06 | 2020-12-16 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
AU2019301811B2 (en) | 2018-07-13 | 2022-05-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
JP7158577B2 (ja) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
KR102650496B1 (ko) | 2018-10-31 | 2024-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제제로서의 치환된 6-아자벤즈이미다졸 화합물 |
EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
JP7350871B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 2’3’-環状ジヌクレオチドおよびそのプロドラッグ |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
BR112022005687A2 (pt) | 2019-09-30 | 2022-06-21 | Gilead Sciences Inc | Vacinas contra o hbv e métodos para tratar o hbv |
US20230031465A1 (en) | 2019-12-06 | 2023-02-02 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
KR20220156884A (ko) | 2020-03-20 | 2022-11-28 | 길리애드 사이언시즈, 인코포레이티드 | 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법 |
AU2021320236A1 (en) | 2020-08-07 | 2023-04-13 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
JP2024518558A (ja) | 2021-05-13 | 2024-05-01 | ギリアード サイエンシーズ, インコーポレイテッド | TLR8調節化合物と抗HBV siRNA治療薬との組合せ |
EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5034393A (en) * | 1989-07-27 | 1991-07-23 | Dowelanco | Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives |
HRP970371A2 (en) * | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
DE60332604D1 (de) | 2002-03-15 | 2010-07-01 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
RS20060018A (en) * | 2003-07-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
CA2576172A1 (en) | 2004-08-23 | 2006-04-06 | Merck & Co., Inc. | Inhibitors of akt activity |
US20110319409A1 (en) * | 2010-06-23 | 2011-12-29 | Cox Christopher D | 7-aza-quinazoline pde10 inhibitors |
GB201112607D0 (en) * | 2011-07-22 | 2011-09-07 | Glaxo Group Ltd | Novel compounds |
LT2970211T (lt) | 2013-03-15 | 2017-10-25 | Quanticel Pharmaceuticals Inc | Histono demetilazės inhibitoriai |
AU2015317806A1 (en) | 2014-09-17 | 2017-04-13 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
-
2014
- 2014-03-12 LT LTEP14768099.5T patent/LT2970211T/lt unknown
- 2014-03-12 PL PL14768099T patent/PL2970211T3/pl unknown
- 2014-03-12 DK DK14768099.5T patent/DK2970211T3/en active
- 2014-03-12 HU HUE14768099A patent/HUE034906T2/hu unknown
- 2014-03-12 RS RS20171070A patent/RS56561B1/sr unknown
- 2014-03-12 EP EP14768099.5A patent/EP2970211B1/en active Active
- 2014-03-12 CA CA2903465A patent/CA2903465A1/en not_active Abandoned
- 2014-03-12 ES ES14768099.5T patent/ES2644828T3/es active Active
- 2014-03-12 PT PT147680995T patent/PT2970211T/pt unknown
- 2014-03-12 WO PCT/US2014/024998 patent/WO2014151106A1/en active Application Filing
- 2014-03-12 US US14/774,335 patent/US9994562B2/en active Active
- 2014-03-12 SI SI201430421T patent/SI2970211T1/sl unknown
- 2014-03-12 JP JP2016501713A patent/JP6332654B2/ja active Active
- 2014-03-12 AU AU2014235280A patent/AU2014235280B2/en not_active Ceased
-
2017
- 2017-10-23 HR HRP20171609TT patent/HRP20171609T1/hr unknown
- 2017-10-23 CY CY20171101101T patent/CY1119476T1/el unknown
-
2018
- 2018-05-04 US US15/971,912 patent/US10526327B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2014235280B2 (en) | 2017-08-31 |
AU2014235280A1 (en) | 2015-09-17 |
SI2970211T1 (sl) | 2017-12-29 |
HRP20171609T1 (hr) | 2017-12-15 |
ES2644828T3 (es) | 2017-11-30 |
JP6332654B2 (ja) | 2018-05-30 |
EP2970211A1 (en) | 2016-01-20 |
US20160039808A1 (en) | 2016-02-11 |
DK2970211T3 (en) | 2017-10-16 |
US20180319793A1 (en) | 2018-11-08 |
PT2970211T (pt) | 2017-10-31 |
EP2970211A4 (en) | 2016-08-03 |
RS56561B1 (sr) | 2018-02-28 |
PL2970211T3 (pl) | 2018-01-31 |
JP2016512834A (ja) | 2016-05-09 |
HUE034906T2 (hu) | 2018-03-28 |
EP2970211B1 (en) | 2017-07-26 |
LT2970211T (lt) | 2017-10-25 |
US10526327B2 (en) | 2020-01-07 |
WO2014151106A1 (en) | 2014-09-25 |
US9994562B2 (en) | 2018-06-12 |
CA2903465A1 (en) | 2014-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119476T1 (el) | Αναστολεις της απομεθυλασης ιστονης | |
CY1119901T1 (el) | Αναστολεις απομεθυλασων ιστονων | |
CY1123906T1 (el) | Αναστολεις απομεθυλασης ιστονης | |
CY1124959T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
CY1123475T1 (el) | Αναστολεις της ειδικης για λυσινη απομεθυλασης-1 | |
CY1120361T1 (el) | Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido) | |
CY1122948T1 (el) | 1η-πυρρολο[2,3-c]πυριδιν-7(6η)-ονες και πυραζολο[3,4-c]πυριδιν-7(6η)-ονες ως αναστολεις των βετ πρωτεϊνων | |
CY1120969T1 (el) | Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης | |
CY1120517T1 (el) | Διαρυλικες ενωσεις χρησιμες για την αγωγη ανθρωπινων νοσων στην ογκολογια, νευρολογια και ανοσολογια | |
CY1121550T1 (el) | Ενωσεις πυριδινης πλαδιενολιδης και μεθοδοι χρησης | |
CY1123581T1 (el) | Νεες μεθοδοι για την παραγωγη ολιγονουκλεοτιδιων | |
CY1119199T1 (el) | Αναστολεις cdc7 | |
CY1119006T1 (el) | Ινδολια | |
CL2019002461A1 (es) | Arn terapéutico. | |
MX2020010496A (es) | Inhibidores de desmetilasa-1 especifica de lisina. | |
CY1120935T1 (el) | Νεες συνθεσεις, χρησεις και μεθοδοι για την παρασκευη αυτων | |
EA201790413A1 (ru) | Антитела против tigit | |
SA515360657B1 (ar) | مثبطات ديميثيلاز هيستون | |
CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
MX2017002824A (es) | Inhibidores demetilasa-1 especifica de lisina. | |
EA201692100A8 (ru) | Новые антитела против rnf43 и способы их применения | |
CY1120459T1 (el) | Αντισωματα των χημειοκινων παν-elr+ cxc | |
MX2020010900A (es) | Inhibidores de demetilasa-1 especifica de lisina. | |
CL2017000659A1 (es) | Inhibidores de histona desmetilasa | |
MA34057B1 (fr) | Compositions et methodes pour le diagnostic et le traitement d'une tumeur |